UNSPSC 51361914: Heptabarb or heptabarbital or heptabarbitone

This classification denotes a barbiturate with the molecular formula C13H18N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V10R70ML23, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(1-cyclohepten-1-yl)-5-ethyl- (9ci) but generally known as heptabarb, which bears US NIH Compound Identifier 10518. European Medicines Agency schedules Heptabarb in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08015MIG. The term HEPTABARB is an International Non-Proprietary Name.

World Health Organization schedules heptabarb in its Anatomical Therapeutic Chemical (ATC) Classification. HEPTABARB is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CCC1(C(=O)NC(=O)NC1=O)C2=CCCCCC2.

UNSPSC 51361914 Heptabarb or heptabarbital or heptabarbitone, a Commodity code, shows minimal relevant recent activity in state and local procurement. The three most recent opportunities associated with this code involve naloxone procurement, direct-to-manufacturer pharmacy prescriptions, and generic multi-source pharmaceuticals—none of which align with the sedative barbiturate compound specified in the code's nominal scope. The mismatch suggests either miscoding in state and local procurement systems or limited actual demand for heptabarbitone under this code designation in the state and local market.

Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023 (note: date appears inconsistent in the source). The Texas Health and Human Services Commission released RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for direct-to-manufacturer prescription programs—an exploratory phase without binding timelines or award values. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 with a March 26, 2026, response deadline for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., effective July 1, 2026. Given the absence of genuine heptabarbitone solicitations and the code's apparent misuse in recent postings, this code warrants a skip for immediate pursuit.